Clinical Trials Browser

Triple Negative Breast Neoplasms × Biosimilar Pharmaceuticals × Breast × Clear all

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms